Triple

T22690161
Position Surface form Disambiguated ID Type / Status
Subject CYP1A2 E561029 entity
Predicate substrateOf P37222 FINISHED
Object theophylline NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: theophylline | Statement: [CYP1A2, substrateOf, theophylline]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: theophylline
Context triple: [CYP1A2, substrateOf, theophylline]
  • A. Docefrez
    Docefrez is a branded formulation of the chemotherapy drug docetaxel used to treat various cancers, including breast, lung, and prostate cancer.
  • B. Fenodyree
    Fenodyree is a mythical, goblin-like creature from Alan Garner’s fantasy novel "The Weirdstone of Brisingamen," known for aiding the protagonists with its otherworldly powers and knowledge of the hidden realms.
  • C. Comethazine
    Comethazine is an American rapper and songwriter known for his aggressive trap style and viral hits like "Walk" and "Bands."
  • D. dextromethorphan
    Dextromethorphan is a common over-the-counter antitussive (cough suppressant) that acts on the central nervous system and is also known for its potential for misuse at high doses.
  • E. Brilique
    Brilique is a brand name for the antiplatelet medication ticagrelor, used to reduce the risk of cardiovascular events such as heart attacks and strokes in patients with acute coronary syndromes or a history of myocardial infarction.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: theophylline
Target entity description: Theophylline is a methylxanthine drug used primarily as a bronchodilator in the treatment of asthma and chronic obstructive pulmonary disease.
  • A. Docefrez
    Docefrez is a branded formulation of the chemotherapy drug docetaxel used to treat various cancers, including breast, lung, and prostate cancer.
  • B. Fenodyree
    Fenodyree is a mythical, goblin-like creature from Alan Garner’s fantasy novel "The Weirdstone of Brisingamen," known for aiding the protagonists with its otherworldly powers and knowledge of the hidden realms.
  • C. Comethazine
    Comethazine is an American rapper and songwriter known for his aggressive trap style and viral hits like "Walk" and "Bands."
  • D. dextromethorphan
    Dextromethorphan is a common over-the-counter antitussive (cough suppressant) that acts on the central nervous system and is also known for its potential for misuse at high doses.
  • E. Brilique
    Brilique is a brand name for the antiplatelet medication ticagrelor, used to reduce the risk of cardiovascular events such as heart attacks and strokes in patients with acute coronary syndromes or a history of myocardial infarction.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454d71b48190a1f80af9f82b6fcf completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1789a1fd08190bce5fa0babe695d3 completed April 29, 2026, 3:18 a.m.
Created at: April 17, 2026, 3:13 p.m.